Design, synthesis, and evaluation of insulin bioconjugates for the application of enhanced basal and glucose-responsive activity

Since its discovery by Banting and Best, the administration of exogenous insulin to control blood glucose levels has been a primary method of treatment for severe cases of diabetes mellitus. Several decades of insulin engineering and development has led to the clinical introduction of two broadly classified categories of protein therapies: prandial and basal insulins. Although these developments have had profound effects on disease management with respect to insulin-dependent diabetes, the overall strategy for development has historically been restricted to rational design criteria based on static pharmacodynamic profiles, profiles that are inherently naive to physiological changes in the diabetic patient. As a result, stringent patient-dependent regimens are the standard of care with regard to glycemic monitoring and management.

Name thesis:degree_name

Doctoral

Department dc:contributor.department

Massachusetts Institute of Technology. Department of Chemical Engineering

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2018

Author dc:creator

• Cortinas, Abel Bryan.

Advisor dc:contributor.advisor

• Daniel G. Anderson.

• Chemical Engineering.

Statement dc:rights

• MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

https://hdl.handle.net/1721.1/121809

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/121809